Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
FLORHAM PARK, N.J., Dec. 15, 2020 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 337,500 shares of common stock. All of the shares to be sold in the offering are to be sold by Phathom. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Share this article
Share this article
NEW YORK, Dec. 15, 2020 /PRNewswire/ American Finance Trust, Inc. (Nasdaq: AFIN) ( AFIN or the Company ) today announced the pricing of an underwritten public offering of 3,200,000 shares of its 7.375% Series C Cumulative Redeemable Perpetual Preferred Stock (the Series C Preferred Stock ) at a gross offering price of $25.00 per share. In addition, the Company has granted the underwriters a 30-day overallotment option to purchase up to an additional 480,000 shares of Series C Preferred Stock. The Company has applied to list the shares of Series C Preferred Stock on the Nasdaq Global Select Market. The Series C Preferred Stock will have a $25.00 liquidation preference per share.
Share this article
Share this article
NEWARK, Calif., Dec. 15, 2020 /PRNewswire/ Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,476,189 shares of its common stock, including 714,285 shares sold pursuant to the underwriters exercise in full of their green shoe option to purchase additional shares, at a price to the public of $21.00 per share. Aggregate gross proceeds to Protagonist from the offering were approximately $115.0 million, before deducting underwriting discounts and commissions and offering expenses.
J.P. Morgan Securities LLC, SVB Leerink LLC, Piper Sandler & Co. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.
American Finance Trust Announces Offering of Series C Cumulative Redeemable Perpetual Preferred Stock prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.